Group 3 Pulmonary Hypertension: From Bench to Bedside.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35482836.
- Also identified by DOI 10.1161/CIRCRESAHA.121.319970 and PMC identifier 9060386.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3 PH in the most recent classification system. Prevalence of these diseases is increasing over time, creating a growing need for effective therapeutic options. Recent approval of the first pulmonary arterial hypertension therapy for the treatment of Group 3 PH related to interstitial lung disease represents an encouraging advancement. This review focuses on molecular mechanisms contributing to pulmonary vasculopathy in chronic hypoxia, the pathology and epidemiology of Group 3 PH, the right ventricular dysfunction observed in this population and clinical trial data that inform the use of pulmonary vasodilators in Group 3 PH.
Medical subject headings
- Hypertension, Pulmonary
- Lung Diseases, Interstitial
- Ventricular Dysfunction, Right